BOLT
Bolt Biotherapeutics
NASDAQ: BOLT · HEALTHCARE · BIOTECHNOLOGY
$4.87
+2.21% today
Updated 2026-04-30
Market cap
$9.28M
P/E ratio
—
P/S ratio
1.21x
EPS (TTM)
$-17.85
Dividend yield
—
52W range
$4 – $9
Volume
0.0M
WallStSmart proprietary scores
42
out of 100
Grade: D
Sell
Investment rating
7.3
Growth
B+5.5
Quality
C+2.5
Profitability
F6.7
Valuation
B3/9
Piotroski F-Score
Weak
-5.9
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$29.00
+496.09%
12-Month target
—
—
Intrinsic (DCF)
$17.18
Margin of safety
+70.90%
0 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Revenue growth 90.10% QoQ
+ 70.90% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -5.85 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-7.16M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $5.73M | $7.88M | $7.69M | $7.70M | $7.70M |
| Net income | $-88.10M | $-69.20M | $-63.12M | $-33.38M | $-6.63M |
| EPS | — | — | — | — | $-17.85 |
| Free cash flow | $-78.46M | $-69.73M | $-61.33M | $-39.92M | $-7.16M |
| Profit margin | -1,537.76% | -878.58% | -820.78% | -433.74% | — |
Peer comparison
Smart narrative
Bolt Biotherapeutics trades at $4.87. Our Smart Value Score of 42/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -5.85, it sits in the distress. TTM revenue stands at $7.70M. Our DCF model estimates intrinsic value at $17.18.
Frequently asked questions
What is Bolt Biotherapeutics's stock price?
Bolt Biotherapeutics (BOLT) trades at $4.87.
Is Bolt Biotherapeutics overvalued?
Smart Value Score 42/100 (Grade D, Sell). DCF value $17.18.
What is the price target of Bolt Biotherapeutics (BOLT)?
The analyst target price is $29.00, representing +496.1% upside from the current price of $4.87.
What is the intrinsic value of Bolt Biotherapeutics (BOLT)?
Based on our DCF model, intrinsic value is $17.18, a +70.9% margin of safety versus $4.87.
What is Bolt Biotherapeutics's revenue?
TTM revenue is $7.70M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
-5.85 — distress.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.21x
ROE-79.70%
Beta0.86
50D MA$4.62
200D MA$5.31
Shares out0.00B
Float0.00B
Short ratio—
Avg volume0.0M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—